Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy: A systematic review about randomized placebo controlled trials;Augmentation von Antidepressiva mit atypischen Antipsychotika bei Nonresponse auf eine Antidepressiva-Monotherapie: Eine systematische Übersichtsarbeit randomisierter placebokontrollierter Studien bei unipolarer nicht wahnhafter Depression

Psychiatrische Praxis

Volumn 39, Issue 2, 2012, Pages 57-63

  Erbe, Sebastian ^a   Gutwinski, Stefan ^b   Bschor, Tom ^a  

^a Schlosspark Klinik   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

atypical antipsychotics; augmentation; treatment resistant depression

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT;

ARTICLE; DELUSION; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM CARBONATE; PATIENT COMPLIANCE; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE;

EID: 84857238165     PISSN: 03034259     EISSN: 14390876     Source Type: Journal    
DOI: 10.1055/s-0031-1277013     Document Type: Article

References (58)

1. Bschor T. Definition, klinisches Bild und Epidemiologie therapieresistenter Depressionen. In: Bschor T. Behandlungsmanual therapieresistente Depression. Pharmakotherapie. Somatische Therapieverfahren. Psychotherapie. Stuttgart Kohlhammer: 2008; 11 16
2. Souery D, Lipp O, Massat I et al. The characterization and definition of treatment-resistant mood disorders. In: Amsterdam JD, Hornig M, Nierenberg AA. Treatment-resistant mood disorders. Cambridge University Press: 2001; 3 29
3. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ. Psychopharmacology: The fourth generation of progress. New York Raven Press: 1995; 1081 1097
4. Rush AJ. Aktueller Stand und Perspektiven der Forschung. In: Bauer M, Berghöfer A, Adli M. Akute und therapieresistente Depressionen. Berlin Springer: 2005; 3 19
5. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry: 1990; 51 39 47 (Pubitemid 20212863)
6. Bschor T, Bauer M. Therapieresistente Depressionen. In: Lemke RM. Affektive Störungen. Stuttgart Thieme: 2004; 101 115
7. Bschor T, Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand: 2010; 121 174 179
8. Friemel S, Bernert S, Angermeyer MC et al. Die direkten Kosten von depressiven Erkrankungen in Deutschland. Ergebnisse aus dem European Study of the Epidemiology of Mental Disorders (ESEMeD) Projekt. Psychiat Prax: 2005; 32 113 121 (Pubitemid 40547829)
9. Spießl H, Hübner-Liebermann B, Hajak G. Volkskrankheit Depression: Epidemiologie, Versorgungssituation, Diagnostik, Therapie und Prävention. Dtsch Med Wochenschr: 2006; 131 35 40
10. Salize HJ, Stamm K, Schubert M et al. Behandlungskosten von Patienten mit Depressionsdiagnose in haus- und fachärztlicher Versorgung in Deutschland. Psychiat Prax: 2004; 31 147 156 (Pubitemid 38506481)
11. Unger HP. Depression und Arbeitswelt. Psychiat Prax: 2007; 34 03 256 260
12. Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des: 2006; 12 2985 2992 (Pubitemid 44184631)
13. Bauer M, Crossley NA, Gerber S et al. The acute antidepressive effects of lithium: from monotherapy to augmentation therapy in major depression. In: Bauer M, Grof P, Müller-Oerlinghausen B. Lithium in neuropsychiatry. The comprehensive guide. London Informa healthcare: 2006; 109 127
14. DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für die Leitliniengruppe Unipolare Depression* S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression. 1 Auflage. Berlin, Düsseldorf DGPPN, ÄZQ, AWMF: 2009; Internet: www.dgppn.de www.versorgungsleitlinien.de www.awmf-leitlinien.de (*Organisationen, die in der Leitliniengruppe kooperierten: DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW, BDK,BDP,BPM,BVDN, BVDP, BVVP, CPKA, DÄVT, DFT, DGGPP, DGPT, DGVT, DPG, DPV, DPtV, DVT, Deutscher Hausärzteverband, GwG, KND)
15. Bauer M, Bschor T, Pfennig A et al. WFSBP Task force on unipolar depressive disorders. World Federation of Societies of Biological Psychiatry (WFSBP). Guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry: 2007; 8 67 104 (Pubitemid 46690921)
16. Bschor T. Augmentationsverfahren. In: Bschor T. Behandlungsmanual therapieresistente Depression. Pharmakotherapie. Somatische Therapieverfahren. Psychotherapie. Stuttgart Kohlhammer: 2008; 114 115
17. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand: 2008; 117 253 259 (Pubitemid 351350599)
18. Philip NS, Carpenter LL, Tyrka AR et al. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J Psychiatr Pract: 2008; 14 34 44 (Pubitemid 351158846)
19. Konstantinidis A, Papageorgiou K, Grohmann R et al. Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychopharmacol: 2011; 17 1 9
20. Papakostas GI, Shelton RC, Smith J et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry: 2007; 68 826 831 (Pubitemid 47015480)
21. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry: 2009; 166 980 991
22. Calabrese JR, Keck PE, Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry: 2005; 162 1351 1360 (Pubitemid 40905587)
23. Thase ME, Macfadden W, Weisler RH et al. BOLDER II Study Group Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol: 2006; 26 600 609 (Pubitemid 44772737)
24. Kirsch I, Sapirstein G. Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention & Treatment: 1998; 1 Article 0002a
25. Stolk P, Ten Berg MJ, Hemels ME et al. Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother: 2003; 37 1891 1899 (Pubitemid 37466590)
26. Bauer M, Whybrow PC, Angst J et al. WFSBP Task force on treatment guidelines for unipolar depressive disorders, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of depressive disorders. World J Biol Psychiatr: 2002; 3 5 43
27. Keller MB, Lavori PW, Mueller TI et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry: 1992; 49 809 816
28. Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant majore depression. Am J Psychiatry: 2001; 158 131 134 (Pubitemid 32047260)
29. Shelton RC, Williamson DJ, Corya SA et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry: 2005; 66 1289 1297 (Pubitemid 41546509)
30. Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment resistant major depressive disorder. J Clin Psychiatry: 2007; 68 224 236 (Pubitemid 46362643)
31. Ostroff RB, Nelson J. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry: 1999; 60 256 259 (Pubitemid 29193925)
32. Mahmoud RA, Pandina GJ, Turkoz I et al. Risperidone for treatment-refractory major depressive disorder. A randomized trial. Ann Intern Med: 2007; 147 593 602 (Pubitemid 351664478)
33. Reeves H, Batra S, May RS et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry: 2008; 69 1228 1236
34. Keitner GI, Garlow SJ, Ryan CE et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res: 2009; 43 205 214
35. th annual meeting of the American Psychiatric Association, Toronto, Canada 2025 May,: 2006
36. th annual meeting of the American Psychiatric Association, Toronto, Canada 2025 May,: 2006
37. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo controlled pilot study. Depress Anxiety: 2007; 24 487 494 (Pubitemid 350086262)
38. Bauer M, Pretorius HW, Constant EL et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry: 2009; 70 540 549
39. El-Khalili N, Joyce M, Atkinson S et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol: 2010; 13 917 932
40. Regen F, Benkert O. Quetiapin - Zulassung als add-on zu Antidepressiva zur Augmentationsbehandlung bei Episoden einer Major Depression. Kompendium News der psychiatrischen Pharmakotherapie. Heidelberg 10. November: 2010; http://www.kompendium-news.de/2010/11/quetiapin-zulassung-als-add-on-zu- antidepressiva-zur-augmentationsbehandlung-bei-episoden-einer-major-depression/ Letzter Zugriff 20.08.2011
41. Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry: 2007; 68 843 853 (Pubitemid 47015482)
42. Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol: 2008; 28 156 165 (Pubitemid 351417120)
43. Berman RM, Fava M, Thase ME et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr: 2009; 14 197 206
44. Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat: 2008; 4 937 948
45. Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des: 2006; 12 2985 2992 (Pubitemid 44184631)
46. Köberle U. Augmentation mit Schilddrüsenhormonen. In: Bschor T. Hrsg. Behandlungsmanual therapieresistente Depression. Pharmakotherapie - somatische Therapieverfahren - Psychotherapie. Stuttgart Kohlhammer: 2008; 129 141
47. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry: 2004; 65 975 981
48. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry: 2007; 68 935 940 (Pubitemid 47015495)
49. Rapaport MH, Gharabawi GM, Canuso CM et al. Effects of risperidone augmentation in patients with treatment-resistant-depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacol: 2006; 31 2505 2513 (Pubitemid 44607069)
50. Bschor T, Berghöfer A, Ströhle A et al. How long should the lithium augmentation strategy be maintained? A 1-Year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol: 2002; 22 427 430 (Pubitemid 34810335)
51. Bauer M, Bschor T, Kunz D et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry: 2000; 157 1429 1435
52. Völkl M, Fritze J, Höffler J et al. Depressionsbehandlung in Deutschland. Eine Analyse zur Wirtschaftlichkeit durch Remission. Gesundh ökon Qual manag: 2007; 12 35 43 (Pubitemid 46391329)
53. König HH, Luppa M, Riedel-Heller S. Die Kosten der Depression und die Wirtschaftlichkeit ihrer Behandlung. Psychiat Prax: 2010; 37 213 215
54. Heres S, Davis J, Maino K et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry: 2006; 163 185 194 (Pubitemid 44480836)
55. Schott G, Pachl H, Limbach U et al. Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen. Teil 1: Qualitative systematische Literaturübersicht zum Einfluss auf Studienergebnisse, -protokoll und -qualität. Dtsch Arztebl Int: 2010; 107 279 285
56. Schott G, Pachl H, Limbach U et al. Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen. Teil 2: Qualitative systematische Literaturübersicht zum Einfluss auf Autorenschaft, Zugang zu Studiendaten sowie auf Studienregistrierung und Publikation. Dtsch Arztebl Int: 2010; 107 295 301
57. Ho BC, Andreasen NC, Ziebell S et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry: 2011; 68 128 137
58. Dore JP, Des Rosiers J, Lew V et al. Quetiapin augmentation of treatment-resistant depression: a comparisation with lithium. Curr Med Res Opin: 2007; 23 333 341 (Pubitemid 46333382)